Breaking News Instant updates and real-time market news.

BLCM

Bellicum Pharmaceuticals

$19.16

0.31 (1.64%)

06:46
11/30/16
11/30
06:46
11/30/16
06:46

Bellicum Pharmaceuticals initiated with a Buy at Ladenburg

Ladenburg analyst Wangzhi Li initiated Bellicum Pharmaceuticals with a Buy and a $31 price target.

  • 03

    Dec

  • 05

    Dec

BLCM Bellicum Pharmaceuticals
$19.16

0.31 (1.64%)

08/22/16
RHCO
08/22/16
NO CHANGE
RHCO
Bellicum Pharmaceuticals price target raised to $30 from $20 at SunTrust
After meeting with Bellicum's management, SunTrust analyst Peter Lawson is more confident that the company's BPX-501 treatment will be approved. He now sees a 50% chance of approval, up from 30% previously, and thinks the treatment could be approved in the U.S. by the end of this year. He keeps a Buy rating on the stock.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
11/01/16
CANT
11/01/16
INITIATION
Target $32
CANT
Buy
Bellicum Pharmaceuticals initiated with a Buy at Cantor
Cantor initiated Bellicum Pharmaceuticals with a Buy and a $32 price target.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.